FDA approves Allergan’s migraine tablet ahead of AbbVie mergerAllergan’s migraine tablet Ubrelvy (ubrogepant) has been approved in the US for the acute treatment of patients with Share XFDA approves Allergan’s migraine tablet ahead of AbbVie mergerhttps://pharmaphorum.com/news/fda-approves-allergans-migraine-tablet-ahead-of-abbvie-merger/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
BeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WMBeiGene’s Brukinsa (zanubrutinib) has failed to outperform its class rival from Johnson & Johnson/AbbVie in the rare white Share XBeiGene’s Brukinsa fails to beat AbbVie/J&J’s Ibrutinib in WMhttps://pharmaphorum.com/news/beigenes-brukinsa-fails-to-beat-abbvie-jjs-ibrutinib-in-wm/
Merck buys ArQule and BTK drug for $2.7bnMerck & Co. has announced it is to snap up ArQule for $2.7 billion, just as the US Share XMerck buys ArQule and BTK drug for $2.7bnhttps://pharmaphorum.com/news/merck-buys-arqule-for/
ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
UCB posts more supportive data from Humira rival bimekizumabThere’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and Share XUCB posts more supportive data from Humira rival bimekizumabhttps://pharmaphorum.com/news/ucb-posts-more-supportive-data-from-humira-rival-bimekizumab/
ICER says ‘marginal’ benefits for AbbVie’s new RA drugAbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as Share XICER says ‘marginal’ benefits for AbbVie’s new RA drughttps://pharmaphorum.com/news/icer-says-marginal-benefits-for-abbvies-new-ra-drug/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
AbbVie signs potential $2.4bn cancer immunotherapy deal with HarpoonAbbVie has signed a deal worth up to $2.4 billion with the US biotech Harpoon Therapeutics, expanding a Share XAbbVie signs potential $2.4bn cancer immunotherapy deal with Harpoonhttps://pharmaphorum.com/news/abbvie-signs-potential-2-4bn/
